Download Polyanalgesic Consensus Conference 2012

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts

Dental emergency wikipedia , lookup

Transcript
INTRATHECAL THERAPY CONSENSUS
Introduction: The use of intrathecal (IT) infusion of analgesic medications to treat patients with chronic refractory pain has
increased since its inception in the 1980s, and the need for clinical research in IT therapy is ongoing. The Polyanalgesic Consensus
Conference (PACC) panel of experts convened in 2000, 2003, and 2007 to make recommendations on the rational use of IT
analgesics based on preclinical and clinical literature and clinical experiences.
Methods: The PACC panel convened again in 2011 to update the standard of care for IT therapies to reflect current knowledge
gleaned from literature and clinical experience. A thorough literature search was performed, and information from this search was
provided to panel members. Analysis of published literature was coupled with the clinical experience of panel members to form
recommendations regarding the use of IT analgesics to treat chronic pain.
Results: After a review of literature published from 2007 to 2011 and discussions of clinical experience, the panel created updated
algorithms for the rational use of IT medications for the treatment of neuropathic pain and nociceptive pain.
Conclusions: The advent of new algorithmic tracks for neuropathic and nociceptive pain is an important step in improving
patient care. The panel encourages continued research and development, including the development of new drugs, devices, and
safety recommendations to improve the care of patients with chronic pain.
Keywords: Chronic pain, consensus, intrathecal
Conflict of Interest: Timothy R. Deer, MD: consulting (Medtronic, Spinal Modulation, St. Jude, Medasys, Bioness, Vertos). Robert
Levy, MD, PhD: consulting (Medtronic and Codman & Shurtleff). Joshua Prager, MD: honoraria (Medtronic, Eli Lily, Qutenza). Allen
Burton, MD: consulting (Medtronic, BSCIS, Stryker), speaking (Azur, Cadence, Cephalon, NeurogesX, Pricara, Pfizer), stockholder
(Vapogenix). Eric Buchser, MD: consulting (Medtronic). David Caraway, MD, PhD: consulting (Medtronic, Spinal Modulation,
MedSys, Codman). Sudhir Diwan, MD: speaking (Neurotherm, BSCI). Eric Grigsby, MD: clinical research (Alfred Mann Foundation,
Medtronic, NeurogesX, Spinal Restoration), speaking (Azur Pharma), consulting (Medtronic, St. Jude Medical, Spinal Modulation,
Vertos, Xalud), stock options (Spinal Modulation, Spinal Restoration, Vertos, Xalud). Marilyn Jacobs, PhD: consulting (Medtronic).
Philip Kim, MD: consulting (Medtronic, Biotronik, Stryker, Azur). Krishna Kumar, MD: consulting and research (Medtronic, Boston
Scientific). Michael Leong, MD: advisor (Covidien). Liong Liem, MD: grant (Spinal Modulation). Gladstone McDowell, MD: speaking
(Azur), consulting (Medtronic, Mysys). Nagy Mekhail, MD, PhD: spe(Endo Pharmaceutical), research (Baylis, Inc., Vertos). Richard
Rauck, MD: research (Medtronic, Medasys, Azur, Codman, Al Mann Foundation), consulting (Medtronic, Medasys, Azur), data and
safety monitoring board membership (Medtronic, Al Mann Foundation). Michael Saulino, MD, PhD: speaking (Medtronic, Azur),
research (Medtronic). Lisa Stearns, MD: research (Medtronic, Insys Therapeutics, Vertos), consulting (Medtronic). Mark Wallace, MD:
research and consulting (Medtronic). K. Dean Willis, MD: speaking (Boston Scientific, Medtronic, St. Jude Medical), Implantable
Systems Performance Registry participant (Medtronic), advisory committee (Boston Scientific). William Witt, MD: consulting
(Medtronic), speaking (Cadence, Pfizer, Medtronic). José De Andrés, MD, PhD; Michael Erdek, MD; Marc Huntoon, MD, PhD; Sunil J.
Panchal, MD; Peter Staats, MD; Michael Stanton-Hicks, MD; B. Todd Sitzman, MD; Michael Cousins, MD: nothing to disclose; and
Tony Yaksh, PhD: consulting (Vertex, Adynxx, Solace, Neuroadjuvants, Trevana), research (Adynxx, Johnson & Johnson, Xenome,
Torrey Pines, Third Rock Ventures, Advanced Targeting Systems, Nektar Pharma, Endo Pharmaceuticals, Sage Rx, Solstice, Epigen).
INTRODUCTION
www.neuromodulationjournal.com
METHODS
A broad literature search was conducted to identify preclinical and
clinical data on IT therapy published from January 15, 2007, through
March 1, 2011. MEDLINE®, BioMed Central®, Current Contents Connect®, Embase, International Pharmaceutical Abstracts®, and Web of
Science® data bases were searched for publications on a range of
medications that are either currently in use or potentially useful for
the IT treatment of chronic pain. Search terms included intrathecal,
intraspinal, morphine, fentanyl, sufentanil, methadone, adenosine,
hydromorphone, meperidine, gabapentin, baclofen, ketorolac, midazolam, neostigmine, octreotide, ziconotide, ropivacaine, dexmedetomidine, clonidine, bupivacaine, and lidocaine. These searches yielded
391 articles, which were examined for relevance to the IT treatment
of chronic pain. Google was also used to search for recent relevant
© 2012 International Neuromodulation Society
Neuromodulation 2012; 15: 436–466
437
The use of intraspinal (intrathecal [IT]) infusion of analgesic medications to treat patients with chronic refractory pain has increased
since its inception in the 1980s, and the need for clinical research in
IT therapy is ongoing. Thus far, research has not kept pace with the
growing need for innovative pain management; therefore, a consensus opinion is needed to clarify the current research and address
deficiencies in the data.
The Polyanalgesic Consensus Conference (PACC) panel first convened in 2000 to address the research gaps and review the existing
data (1). This expert panel is composed of physicians and other
clinicians in the field of IT therapy. The panel developed an IT drug
selection algorithm on the basis of best evidence and expert
opinion and prepared supplemental reports that included a literature review, documentation of results from a survey of peers regarding IT therapy, and projections for future directions in the field of IT
therapy. The PACC panel reconvened in 2003 (2) and 2007 (3) to
evaluate the most recent literature and to update the algorithm for
intraspinal drug selection. In 2011, to formulate consensus opinions
on critical issues involving IT therapy and identify areas for future
research in the field, the PACC panel again convened, with objec-
tives of modifying and updating the IT drug selection algorithm by
reviewing previous PACC guidelines including literature published
before January 14, 2007; preclinical and clinical data on IT therapy
published from January 15, 2007, through March 1, 2011; and
results of a peer survey.